Business

Gilead Sciences recently announced the success of its experimental twice-yearly medicine, lenacapavir, in preventing HIV in a late-stage trial. The results of the trial showed that all 2,000 women who received the shot remained HIV-free, prompting optimism in the fight against the virus. This breakthrough could revolutionize the landscape of HIV prevention and treatment, providing
0 Comments